AtriCure Reports Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
AtriCure Inc. (ATRC) PT Raised to $92 at Needham & Company
November 4, 2021 6:44 AM EDTNeedham & Company analyst Mike Matson raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $92.00 (from $90.00) while maintaining a Buy rating.
The analyst commented, "ATRC's 3Q21 revenue, EBITDA, and EPS all beat consensus. While it has only been 6 months since EPi-Sense's FDA... More
AtriCure (ATRC) Tops Q3 EPS by 10c
November 3, 2021 4:39 PM EDTAtriCure (NASDAQ: ATRC) reported Q3 EPS of ($0.23), $0.10 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $70.5 million versus the consensus estimate of $68.68 million.
GUIDANCE:
AtriCure sees FY2021 EPS of ($1.20), versus the consensus of ($1.35). AtriCure... More
